DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
DiaMedica Therapeutics announced the dosing of the first patients in a Phase 2 investigator-sponsored trial evaluating DM199 for fetal growth restriction (FGR). The open-label study is designed to enroll up to 30 patients to assess safety and explore efficacy endpoints such as uterine artery vascular resistance and fetal growth trajectory.
Key figures
- Drug Name
- DM199
- Phase Of Trial
- Phase 2
- Trial design
- open-label, single-arm
- Enrollment target
- up to 30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.